UroGen Pharma Accelerates Growth with Executive Equity Grants!

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company devoted to creating and commercializing transformative treatments for urothelial and specialty cancers, has granted inducement restricted stock units (“RSUs”) to seven new employees in order to strengthen their workforce. This move comes as the company gears up to launch Jelmyto® (mitomycin) for pyelocalyceal solution and further develop their pipeline. The RSUs were granted between March 1 and March 6, 2023. With the addition of this new team, UroGen can take the next steps to revolutionize the treatment of these cancers.

UroGen is offering up to 11,700 shares of its common stock to reward employees for their ongoing service. The RSUs vesting process is spread out over three years, with one third of the underlying shares vesting each year on the anniversary of the vesting date. This ensures that employees are rewarded for their hard work and dedication over the long-term.

UroGen has granted RSUs to each employee as a form of inducement upon entering into employment with the company, in compliance with Nasdaq listing Rule 5635(c)(4). These RSU grants are subject to the terms and conditions of UroGen’s 2019 Inducement Plan, as outlined in the RSU grant notice and agreement.

About UroGen Pharma Ltd.

UroGen is a biotech company on a mission to revolutionize the treatment of urothelial and specialty cancers with its innovative RTGelTM reverse-thermal hydrogel platform technology. RTGelTM has the potential to improve therapeutic profiles of existing drugs, enabling longer exposure of the urinary tract tissue to medications and making local therapy a more effective treatment option. UroGen’s first two products, Jelmyto® (mitomycin) for pyelocaliceal solution and UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors without the need for surgery. Based in Princeton, New Jersey, with additional operations in Israel, UroGen is dedicated to providing better options for cancer patients.

Leave a Comment